Literature DB >> 18029122

Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs.

J Hongrapipat1, P Kopecková, S Prakongpan, J Kopecek.   

Abstract

The synergism in anticancer effect toward human renal carcinoma A498 cells by binary combinations of free and N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound anticancer drugs, SOS thiophene (SOS), doxorubicin (DOX), and mesochlorin e6 monoethylenediamine (Mce6), was evaluated. The combination index (CI) analysis was used to quantify the synergism, antagonism, and additive effects. Both free drugs and HPMA copolymer conjugates, when used as single agents or in combination, exhibited cytotoxic activities against A498 cells, as determined using a modified MTT assay. As single agents, SOS and P-GFLG-SOS (HPMA copolymer conjugates containing SOS bound via glycylphenylalanylleucylglycine [GFLG] spacer) were significantly more effective than the other agents evaluated. The synergistic effects ranked in the order SOS+DOX>P-GFLG-DOX+P-GFLG-Mce6 approximately DOX+Mce6>P-GFLG-SOS+P-GFLG-DOX approximately SOS+Mce6>P-GFLG-SOS+P-GFLG-Mce6. The combination of SOS+DOX proved to be synergistic over all cell growth inhibition levels. All other combinations exhibited synergism in a wide range of drug effect levels. The SOS+Mce6 and P-GFLG-SOS+P-GFLG-Mce6 combinations displayed synergism up to drug affected fraction (fa) values of about 0.8 and reached slight antagonism and nearly additivity at fa=0.95, respectively. However, all other combinations were synergistic up to fa<0.9 and were additive at higher fa values. The observations that most combinations produced synergistic effects will be important for clinical translation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18029122      PMCID: PMC2270786          DOI: 10.1016/j.ijpharm.2007.09.018

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  75 in total

1.  Polymer therapeutics designed for a combination therapy of hormone-dependent cancer.

Authors:  María J Vicent; Francesca Greco; Robert I Nicholson; Alison Paul; Peter C Griffiths; Ruth Duncan
Journal:  Angew Chem Int Ed Engl       Date:  2005-06-27       Impact factor: 15.336

2.  Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.

Authors:  John D Hainsworth; Jeffrey A Sosman; David R Spigel; Donna L Edwards; Cara Baughman; Anthony Greco
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

Review 3.  Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens.

Authors:  R J Amato
Journal:  Ann Oncol       Date:  2005-01       Impact factor: 32.976

4.  Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.

Authors:  Ryan H Shanks; David A Rizzieri; James L Flowers; O Michael Colvin; David J Adams
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

5.  Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl) methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice.

Authors:  C M Peterson; J M Lu; Y Sun; C A Peterson; J G Shiah; R C Straight; J Kopecek
Journal:  Cancer Res       Date:  1996-09-01       Impact factor: 12.701

6.  Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses.

Authors:  Liang Zhao; M Guillaume Wientjes; Jessie L-S Au
Journal:  Clin Cancer Res       Date:  2004-12-01       Impact factor: 12.531

7.  Isobolographic assessment of the interaction between adriamycin and photodynamic therapy with meso-chlorin e6 monoethylene diamine in human epithelial ovarian carcinoma (OVCAR-3) in vitro.

Authors:  C M Peterson; J M Lu; Z W Gu; J G Shiah; K Lythgoe; C A Peterson; R C Straight; J Kopecek
Journal:  J Soc Gynecol Investig       Date:  1995 Nov-Dec

8.  Combined effects of radiotherapy and photodynamic therapy on an in vitro human prostate model.

Authors:  Alberto Colasanti; Annamaria Kisslinger; Maria Quarto; Patrizia Riccio
Journal:  Acta Biochim Pol       Date:  2004       Impact factor: 2.149

9.  p53 regulation and function in renal cell carcinoma.

Authors:  Hazel E Warburton; Mark Brady; Nikolina Vlatković; W Marston Linehan; Keith Parsons; Mark T Boyd
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

10.  Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.

Authors:  S M Harris; P Mistry; C Freathy; J L Brown; P A Charlton
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

View more
  8 in total

1.  Polymeric conjugates for drug delivery.

Authors:  Nate Larson; Hamidreza Ghandehari
Journal:  Chem Mater       Date:  2012-01-04       Impact factor: 9.811

2.  Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells.

Authors:  Acharaporn Duangjai; Kui Luo; Yan Zhou; Jiyuan Yang; Jindřich Kopeček
Journal:  Eur J Pharm Biopharm       Date:  2013-12-04       Impact factor: 5.571

3.  POLYMERIC BIOMATERIALS AND NANOMEDICINES.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Drug Deliv Sci Technol       Date:  2015-12-01       Impact factor: 3.981

Review 4.  Biological rationale for the design of polymeric anti-cancer nanomedicines.

Authors:  Yan Zhou; Jindřich Kopeček
Journal:  J Drug Target       Date:  2012-09-26       Impact factor: 5.121

Review 5.  Macromolecular therapeutics.

Authors:  Jiyuan Yang; Jindřich Kopeček
Journal:  J Control Release       Date:  2014-04-18       Impact factor: 9.776

Review 6.  Polymer-drug conjugates: origins, progress to date and future directions.

Authors:  Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

7.  HPMA copolymers: origins, early developments, present, and future.

Authors:  Jindrich Kopecek; Pavla Kopecková
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

8.  Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells.

Authors:  Jarunee Hongrapipat; Pavla Kopecková; Jihua Liu; Sompol Prakongpan; Jindrich Kopecek
Journal:  Mol Pharm       Date:  2008-08-27       Impact factor: 4.939

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.